Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice

2002 ◽  
Vol 69 (2) ◽  
pp. 163-172 ◽  
Author(s):  
Takami Akagi ◽  
Masaki Kawamura ◽  
Masamichi Ueno ◽  
Katsuya Hiraishi ◽  
Masakazu Adachi ◽  
...  
Keyword(s):  
Antibody Response ◽  
Mucosal Immunization ◽  
Hiv 1

Inverse relationship between HIV-1 p24 antigenemia, anti-p24 antibody and neutralizing antibody response in all stages of HIV-1 infection

1989 ◽  
Vol 20 (3) ◽  
pp. 223-230 ◽  
Author(s):  
Y. Sei ◽  
P.H. Tsang ◽  
F.N. Chu ◽  
I. Wallace ◽  
J.P. Roboz ◽  
...  
Keyword(s):  
Antibody Response ◽  
Inverse Relationship ◽  
Neutralizing Antibody ◽  
Hiv 1

B-Cell Abnormalities in AIDS: Stable and Clonally-Restricted Antibody Response in HIV-1 Infection

1993 ◽  
Vol 38 (4) ◽  
pp. 327-334 ◽  
Author(s):  
S. MULLER ◽  
H. WANG ◽  
G. J. SILVERMAN ◽  
G. BRAMLET ◽  
N. HAIGWOOD ◽  
...  
Keyword(s):  
Antibody Response ◽  
B Cell ◽  
Hiv 1

Antibody response to the viral negative factor (nef) in HIV-1 infection

AIDS ◽  
1989 ◽  
Vol 3 (4) ◽  
pp. 227-234 ◽  
Author(s):  
Peter Reiss ◽  
Anthony de Ronde ◽  
Joep M.A. Lange ◽  
Frank de Wolf ◽  
John Dekker ◽  
...  
Keyword(s):  
Antibody Response ◽  
Negative Factor ◽  
Hiv 1

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

AIDS ◽  
2011 ◽  
Vol 25 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Anna Kajaste-Rudnitski ◽  
Laura Galli ◽  
Silvia Nozza ◽  
Giuseppe Tambussi ◽  
Andrea Di Pietro ◽  
...  
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Protective Antibody ◽  
Hiv 1

scholarly journals HIV-1 Superinfection in Women Broadens and Strengthens the Neutralizing Antibody Response

2012 ◽  
Vol 8 (3) ◽  
pp. e1002611 ◽  
Author(s):  
Valerie Cortez ◽  
Katherine Odem-Davis ◽  
R. Scott McClelland ◽  
Walter Jaoko ◽  
Julie Overbaugh
Keyword(s):  
Antibody Response ◽  
Neutralizing Antibody ◽  
Hiv 1

scholarly journals Filaria specific antibody response profiling in plasma from anti-retroviral naïve Loa loa microfilaraemic HIV-1 infected people

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Ghislain Donald Njambe Priso ◽  
Abel Lissom ◽  
Loveline N. NGU ◽  
Nadesh N. Nji ◽  
Jules Colince Tchadji ◽  
...  
Keyword(s):  
Antibody Response ◽  
Specific Antibody ◽  
Loa Loa ◽  
Specific Antibody Response ◽  
Infected People ◽  
Hiv 1

scholarly journals Dynamical analysis model of HIV-1 infection in CD4+ T cells with antibody response

2020 ◽  
Vol 1524 ◽  
pp. 012128
Author(s):  
A H Permatasari ◽  
Sutimin ◽  
S Khabibah ◽  
D A Munawwaroh ◽  
R H S Utomo
Keyword(s):  
T Cells ◽  
Antibody Response ◽  
Cd4 T Cells ◽  
Dynamical Analysis ◽  
Analysis Model ◽  
Hiv 1

scholarly journals Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

2007 ◽  
Vol 15 (2) ◽  
pp. 253-259 ◽  
Author(s):  
P. Durando ◽  
D. Fenoglio ◽  
A. Boschini ◽  
F. Ansaldi ◽  
G. Icardi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Influenza Virus ◽  
Antibody Response ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Geometric Mean ◽  
Subunit Vaccines ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immunogenicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.

scholarly journals Demographic Factors That Influence the Neutralizing Antibody Response in Recipients of Recombinant HIV‐1 gp120 Vaccines

2004 ◽  
Vol 190 (11) ◽  
pp. 1962-1969 ◽  
Author(s):  
David C. Montefiori ◽  
Barbara Metch ◽  
M. Juliana McElrath ◽  
Steve Self ◽  
Kent J. Weinhold ◽  
...  
Keyword(s):  
Antibody Response ◽  
Demographic Factors ◽  
Neutralizing Antibody ◽  
Hiv 1

scholarly journals 4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response

2007 ◽  
Vol 82 (5) ◽  
pp. 2367-2375 ◽  
Author(s):  
Elin S. Gray ◽  
Penny L. Moore ◽  
Frederic Bibollet-Ruche ◽  
Hui Li ◽  
Julie M. Decker ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antibody Response ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Neutralizing Antibody ◽  
Subtype C ◽  
External Region ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT The broadly neutralizing monoclonal antibody (MAb) 4E10 recognizes a linear epitope in the C terminus of the membrane-proximal external region (MPER) of gp41. This epitope is particularly attractive for vaccine design because it is highly conserved among human immunodeficiency virus type 1 (HIV-1) strains and neutralization escape in vivo has not been observed. Multiple env genes were cloned from an HIV-1 subtype C virus isolated from a 7-year-old perinatally infected child who had anti-MPER neutralizing antibodies. One clone (TM20.13) was resistant to 4E10 neutralization as a result of an F673L substitution in the MPER. Frequency analysis showed that F673L was present in 33% of the viral variants and in all cases was linked to the presence of an intact 2F5 epitope. Two other envelope clones were sensitive to 4E10 neutralization, but TM20.5 was 10-fold less sensitive than TM20.6. Substitutions at positions 674 and 677 within the MPER rendered TM20.5 more sensitive to 4E10 but had no effect on TM20.6. Using chimeric and mutant constructs of these two variants, we further demonstrated that the lentivirus lytic peptide-2 domain in the cytoplasmic tail affected the accessibility of the 4E10 epitope, as well as virus infectivity. Collectively, these genetic changes in the face of a neutralizing antibody response to the MPER strongly suggested immune escape from antibody responses targeting this region.

Sign in / Sign up

Export Citation Format

Share Document